The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

Credit: SewCreamStudio / Shutterstock. Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised neoantigen therapy, in combination with ...

Analysts forecast 'Sales- Oncology- Keytruda' to reach $7.38 billion ... analysts suggests that 'Sales- Oncology- Alliance revenue- Lenvima' will likely reach $275.08 million.

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

In oncology drugs, Keytruda sales are likely to have been ... Alliance revenues from Lenvima may have also boosted oncology sales. Sales of Welireg are likely to have been driven by the launch ...

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...